Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||no benefit||Buparlisib||Phase II||Actionable||In a Phase II trial, Buparlisib (BKM120) treatment in patients with triple-negative breast cancer (TNBC) resulted in median progression-free survival of 1.8 months, median overall survival of 11.2 months, stable disease lasting more than four months in 12% (6/50) of patients, and no objective responses, and due to the limited clinical efficacy, further study as a single agent in TNBC patients was not supported (PMID: 33138866; NCT01790932, NCT01629615).||33138866|